Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.55 |
| ▸ | STK3 | Q13188 | 8/20 | 0.51 |
| ▸ | STK4 | Q13043 | 6/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.49 |
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | BTK | Q06187 | 2/20 | 0.46 |
| ▸ | STK25 | O00506 | 1/20 | 0.46 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | GAK | O14976 | 1/20 | 0.46 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.46 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.46 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.46 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.46 |
| ▸ | STK17B | O94768 | 1/20 | 0.46 |
| ▸ | STK10 | O94804 | 1/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12908946 | 0.91 | EGFR (0.53) | EGFRSTK3STK4ERBB2 | |
| SCHEMBL939980 | 0.88 | EGFR (0.74) | EGFRSTK3STK4ERBB2SRC | |
| SCHEMBL939978 | 0.88 | EGFR (0.74) | EGFRSTK3STK4ERBB2SRC | |
| SCHEMBL938069 | 0.86 | EGFR (0.57) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL938524 | 0.84 | EGFR (0.67) | EGFRERBB2SRC | |
| SCHEMBL938318 | 0.83 | STK3 (0.52) | EGFRSTK3STK4ERBB2SRC | |
| SCHEMBL938914 | 0.82 | EGFR (0.74) | EGFRERBB2 | |
| SCHEMBL938568 | 0.81 | EGFR (0.60) | EGFRERBB2KCNH2ERBB4 | |
| SCHEMBL12908987 | 0.78 | MKNK1 (0.56) | EGFRERBB2ERBB4 | |
| SCHEMBL1020025 | 0.77 | EGFR (0.70) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524722-B2 | Substituted tricyclic compounds and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-03 | — | — | US | disclosed |
| EP-2212332-B1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER IP GMBH (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-20110021493-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021493-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2212332-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009033581-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021493-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | CYP11B2, CYP11B1, CYP11A1 | EGFR 1771/4885STK3 2021/4885STK4 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.